Barriers and Challenges in Biomarker Testing for ALK+ NSCLC

Opinion
Video

Dr. Garon discusses the factors that make a patient a strong candidate for ALK inhibitor therapy in ALK+ NSCLC, the importance of biomarker testing in guiding treatment selection, and his approach to testing along with challenges encountered, especially in community settings.

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with ALK+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN.

  1. Dr. Thawani asks Dr Garon: What factors make this patient a strong candidate for ALK inhibitor therapy?
  • How critical is biomarker testing in guiding treatment selection?
  • Could you share your approach to biomarker testing and any barriers faced, particularly in community settings?
Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
Wildfire Exposure Confers Longer Length of Stay Following NSCLC Surgery | Image Credit: © appledesign - stock.adobe.com.

Wildfire Exposure Confers Longer Length of Stay Following NSCLC Surgery

Russ Conroy
March 20th 2025
Article

Future work may need to assess whether extended hospital stays improve surgical care outcomes during disasters, according to one of the study authors.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Use of Deep-IO may help refine treatment precision and identify patients with advanced NSCLC who are likely to benefit from immune checkpoint inhibitors.

AI Model May Predict Immunotherapy Responses in Advanced NSCLC

Russ Conroy
March 12th 2025
Article

Use of Deep-IO may help refine treatment precision and identify patients with advanced NSCLC who are likely to benefit from immune checkpoint inhibitors.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Phase 2 data support further investigation of trastuzumab rezetecan as a treatment for patients with HER2-mutant non–small cell lung cancer.

Novel ADC Elicits Meaningful Activity in Pretreated HER2-Mutant NSCLC

Russ Conroy
March 10th 2025
Article

Phase 2 data support further investigation of trastuzumab rezetecan as a treatment for patients with HER2-mutant non–small cell lung cancer.

Ivonescimab Prolonged PFS vs Pembrolizumab in PD-L1+, Treatment-Naïve NSCLC

Ivonescimab Prolonged PFS vs Pembrolizumab in PD-L1+, Treatment-Naïve NSCLC

Tim Cortese
March 10th 2025
Article

Ivonescimab demonstrated a broad prolongation of PFS across various prespecified subgroups in patients with treatment-naïve, PD-L1–positive NSCLC.